RT Journal Article
T1 HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients.
A1 Castellsagué, Xavier
A1 Alemany, Laia
A1 Quer, Miquel
A1 Halec, Gordana
A1 Quirós, Beatriz
A1 Tous, Sara
A1 Clavero, Omar
A1 Alòs, Llúcia
A1 Biegner, Thorsten
A1 Szafarowski, Tomasz
A1 Alejo, Maria
A1 Holzinger, Dana
A1 Cadena, Enrique
A1 Claros, Edith
A1 Hall, Gillian
A1 Laco, Jan
A1 Poljak, Mario
A1 Benevolo, Maria
A1 Kasamatsu, Elena
A1 Mehanna, Hisham
A1 Ndiaye, Cathy
A1 Guimerà, Núria
A1 Lloveras, Belen
A1 León, Xavier
A1 Ruiz-Cabezas, Juan C
A1 Alvarado-Cabrero, Isabel
A1 Kang, Chang-Suk
A1 Oh, Jin-Kyoung
A1 Garcia-Rojo, Marcial
A1 Iljazovic, Ermina
A1 Ajayi, Oluseyi F
A1 Duarte, Flora
A1 Nessa, Ashrafun
A1 Tinoco, Leopoldo
A1 Duran-Padilla, Marco A
A1 Pirog, Edyta C
A1 Viarheichyk, Halina
A1 Morales, Hesler
A1 Costes, Valérie
A1 Félix, Ana
A1 Germar, Maria Julieta V
A1 Mena, Marisa
A1 Ruacan, Arzu
A1 Jain, Asha
A1 Mehrotra, Ravi
A1 Goodman, Marc T
A1 Lombardi, Luis Estuardo
A1 Ferrera, Annabelle
A1 Malami, Sani
A1 Albanesi, Estela I
A1 Dabed, Pablo
A1 Molina, Carla
A1 López-Revilla, Rubén
A1 Mandys, Václav
A1 González, Manuel E
A1 Velasco, Julio
A1 Bravo, Ignacio G
A1 Quint, Wim
A1 Pawlita, Michael
A1 Muñoz, Nubia
A1 de Sanjosé, Silvia
A1 Xavier Bosch, F
A1 ICO International HPV in Head and Neck Cancer Study Group, 
AB We conducted a large international study to estimate fractions of head and neck cancers (HNCs) attributable to human papillomavirus (HPV-AFs) using six HPV-related biomarkers of viral detection, transcription, and cellular transformation. Formalin-fixed, paraffin-embedded cancer tissues of the oral cavity (OC), pharynx, and larynx were collected from pathology archives in 29 countries. All samples were subject to histopathological evaluation, DNA quality control, and HPV-DNA detection. Samples containing HPV-DNA were further subject to HPV E6*I mRNA detection and to p16(INK4a), pRb, p53, and Cyclin D1 immunohistochemistry. Final estimates of HPV-AFs were based on HPV-DNA, HPV E6*I mRNA, and/or p16(INK4a) results. A total of 3680 samples yielded valid results: 1374 pharyngeal, 1264 OC, and 1042 laryngeal cancers. HPV-AF estimates based on positivity for HPV-DNA, and for either HPV E6*I mRNA or p16(INK4a), were 22.4%, 4.4%, and 3.5% for cancers of the oropharynx, OC, and larynx, respectively, and 18.5%, 3.0%, and 1.5% when requiring simultaneous positivity for all three markers. HPV16 was largely the most common type. Estimates of HPV-AF in the oropharynx were highest in South America, Central and Eastern Europe, and Northern Europe, and lowest in Southern Europe. Women showed higher HPV-AFs than men for cancers of the oropharynx in Europe and for the larynx in Central-South America. HPV contribution to HNCs is substantial but highly heterogeneous by cancer site, region, and sex. This study, the largest exploring HPV attribution in HNCs, confirms the important role of HPVs in oropharyngeal cancer and drastically downplays the previously reported involvement of HPVs in the other HNCs.
YR 2016
FD 2016-01-28
LK http://hdl.handle.net/10668/9791
UL http://hdl.handle.net/10668/9791
LA en
DS RISalud
RD Apr 11, 2025